Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

294.16 -1.06 (-0.36%)
Streaming Delayed Price Updated: 12:45 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 189,261
Open 295.66
Bid (Size) 293.86 (1)
Ask (Size) 294.35 (2)
Prev. Close 295.22
Today's Range 291.13 - 298.30
52wk Range 266.98 - 417.81
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors. 
Via Chartmill
1 Mid-Cap Stock with Exciting Potential and 2 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory

Performance

YTD
-18.3%
-18.3%
1 Month
-9.6%
-9.6%
3 Month
-5.8%
-5.8%
6 Month
-18.3%
-18.3%
1 Year
-7.2%
-7.2%

More News

Read More
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Forecasting The Future: 7 Analyst Projections For United Therapeutics
Via Benzinga
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
Via Chartmill
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?
Via Benzinga
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 to Keep Off Your Radar
Via StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
Via Chartmill
Dow Gains 50 Points; US Small Business Optimism Index Rises In May
Via Benzinga
Topics Stocks
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge
Via Benzinga
Topics Intellectual Property
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
Via Chartmill
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Via StockStory
Topics Artificial Intelligence
1 Safe-and-Steady Stock on Our Buy List and 2 to Ignore
Via StockStory
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
Via StockStory
Topics Artificial Intelligence
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central
Via StockStory
Examining the Quality Attributes of UNITED THERAPEUTICS CORP (NASDAQ:UTHR).
Via Chartmill
3 Big Reasons to Love United Therapeutics (UTHR)
Via StockStory
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Following Peter Lynch’s approach: Does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fit the bill?
Via Chartmill

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 294.16
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 07/03/25 12:45 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 13.21B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.